Exclusive: Two M&A deals and $9B later, Lonnie Moulder is ramping up his latest biotech startup. And this one comes with global vision built in

Lonnie Moulder may have been in silent running mode in the 2 years since he closed the $5 billion sale of Tesaro to GlaxoSmithKline …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Ex­clu­sive: Two M&A deals and $9B lat­er, Lon­nie Moul­der is ramp­ing up his lat­est biotech start­up. And this one comes with glob­al vi­sion built in